Φορτώνει......
Twenty years of anti-HER2 therapy-associated cardiotoxicity
Over the past 20 years, the prognosis of HER2-positive breast cancer has been transformed by the development of anti-HER2 targeted therapies. In early clinical trials of trastuzumab (ie, the first anti-HER2 agent to be developed) cardiotoxicity became a major concern. In the first published phase 3...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | ESMO Open |
|---|---|
| Κύριοι συγγραφείς: | , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
BMJ Publishing Group
2016
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5070246/ https://ncbi.nlm.nih.gov/pubmed/27843627 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2016-000073 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|